...
alxo-img

Alx Oncology Holdings , Common Stock

ALXO

NSQ

$1.72

+$0.1

(6.17%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$95.47M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
726.77K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.19 L
$17.82 H
$1.72

About Alx Oncology Holdings , Common Stock

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALXOSectorS&P500
1-Week Return3.61%-1.95%0.69%
1-Month Return16.22%-3.36%1.53%
3-Month Return-18.1%-6.93%11.27%
6-Month Return-80.16%-1.83%13.49%
1-Year Return-86.24%8.53%31.62%
3-Year Return-94.36%7.58%30.33%
5-Year Return-94.27%44.7%93.83%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue4.80M1.18M---[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.65,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue4.36M1.07M736.00K1.47M836.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.66,"profit":true},{"date":"2021-12-31","value":16.88,"profit":true},{"date":"2022-12-31","value":33.62,"profit":true},{"date":"2023-12-31","value":19.17,"profit":true}]
Gross Profit436.00K107.00K(736.00K)(1.47M)(836.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.54,"profit":true},{"date":"2021-12-31","value":-168.81,"profit":false},{"date":"2022-12-31","value":-336.24,"profit":false},{"date":"2023-12-31","value":-191.74,"profit":false}]
Gross Margin9.09%9.05%---[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.58,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses19.62M43.77M83.56M127.44M170.28M[{"date":"2019-12-31","value":11.52,"profit":true},{"date":"2020-12-31","value":25.71,"profit":true},{"date":"2021-12-31","value":49.07,"profit":true},{"date":"2022-12-31","value":74.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(19.18M)(43.66M)(83.56M)(127.44M)(170.28M)[{"date":"2019-12-31","value":-1918300000,"profit":false},{"date":"2020-12-31","value":-4366300000,"profit":false},{"date":"2021-12-31","value":-8355500000,"profit":false},{"date":"2022-12-31","value":-12743600000,"profit":false},{"date":"2023-12-31","value":-17027800000,"profit":false}]
Total Non-Operating Income/Expense(47.00K)(2.65M)58.00K8.30M18.56M[{"date":"2019-12-31","value":-0.25,"profit":false},{"date":"2020-12-31","value":-14.26,"profit":false},{"date":"2021-12-31","value":0.31,"profit":true},{"date":"2022-12-31","value":44.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(19.21M)(45.50M)(83.48M)(123.42M)(160.81M)[{"date":"2019-12-31","value":-1920900000,"profit":false},{"date":"2020-12-31","value":-4549900000,"profit":false},{"date":"2021-12-31","value":-8348400000,"profit":false},{"date":"2022-12-31","value":-12341800000,"profit":false},{"date":"2023-12-31","value":-16080500000,"profit":false}]
Income Taxes34.00K241.00K(21.00K)64.00K-[{"date":"2019-12-31","value":14.11,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-8.71,"profit":false},{"date":"2022-12-31","value":26.56,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(19.24M)(45.74M)(83.46M)(123.48M)-[{"date":"2019-12-31","value":-1924300000,"profit":false},{"date":"2020-12-31","value":-4574000000,"profit":false},{"date":"2021-12-31","value":-8346300000,"profit":false},{"date":"2022-12-31","value":-12348200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(19.24M)(45.74M)(83.46M)(123.48M)(160.81M)[{"date":"2019-12-31","value":-1924300000,"profit":false},{"date":"2020-12-31","value":-4574000000,"profit":false},{"date":"2021-12-31","value":-8346300000,"profit":false},{"date":"2022-12-31","value":-12348200000,"profit":false},{"date":"2023-12-31","value":-16080500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(19.24M)(45.74M)(83.46M)(123.48M)(160.81M)[{"date":"2019-12-31","value":-1924300000,"profit":false},{"date":"2020-12-31","value":-4574000000,"profit":false},{"date":"2021-12-31","value":-8346300000,"profit":false},{"date":"2022-12-31","value":-12348200000,"profit":false},{"date":"2023-12-31","value":-16080500000,"profit":false}]
EPS (Diluted)-(4.47)(2.06)(3.03)(3.75)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-446.85,"profit":false},{"date":"2021-12-31","value":-206,"profit":false},{"date":"2022-12-31","value":-303,"profit":false},{"date":"2023-12-31","value":-375,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALXO
Cash Ratio 4.59
Current Ratio 4.82

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALXO
ROA (LTM) -49.25%
ROE (LTM) -98.94%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALXO
Debt Ratio Lower is generally better. Negative is bad. 0.26
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALXO
Trailing PE NM
Forward PE NM
P/S (TTM) 5906.24
P/B 0.62
Price/FCF NM
EV/R 4254.36
EV/Ebitda NM

FAQs

What is Alx Oncology Holdings  share price today?

Alx Oncology Holdings  (ALXO) share price today is $1.72

Can Indians buy Alx Oncology Holdings  shares?

Yes, Indians can buy shares of Alx Oncology Holdings  (ALXO) on Vested. To buy Alx Oncology Holdings  from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALXO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Alx Oncology Holdings  be purchased?

Yes, you can purchase fractional shares of Alx Oncology Holdings  (ALXO) via the Vested app. You can start investing in Alx Oncology Holdings  (ALXO) with a minimum investment of $1.

How to invest in Alx Oncology Holdings  shares from India?

You can invest in shares of Alx Oncology Holdings  (ALXO) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALXO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Alx Oncology Holdings  shares
What is Alx Oncology Holdings  52-week high and low stock price?

The 52-week high price of Alx Oncology Holdings  (ALXO) is $17.82. The 52-week low price of Alx Oncology Holdings  (ALXO) is $1.19.

What is Alx Oncology Holdings  price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Alx Oncology Holdings  (ALXO) is

What is Alx Oncology Holdings  price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Alx Oncology Holdings  (ALXO) is 0.62

What is Alx Oncology Holdings  dividend yield?

The dividend yield of Alx Oncology Holdings  (ALXO) is 0.00%

What is the Market Cap of Alx Oncology Holdings ?

The market capitalization of Alx Oncology Holdings  (ALXO) is $95.47M

What is Alx Oncology Holdings ’s stock symbol?

The stock symbol (or ticker) of Alx Oncology Holdings  is ALXO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top